On Monday, the Federal Circuit made a decision to reconsider the interpretation of critical terminology relating to a patent lawsuit brought against Viatris, a leading pharmaceutical company. The lawsuit pertains to a treatment for blood pressure, and the court has signalled the need for the reevaluation of additional evidence. This development came after a district judge in West Virginia had previously passed a judgment concerning the case.
Complete details regarding the ongoing lawsuit can be assessed on Law360
The Federal Circuit’s decision presents an unexpected turn in the case and offers Viatris a renewed opportunity to argue their stance on the contested patent against Actelion. Legal professionals will closely monitor further develpments in the case as they can potentially influence patent litigation strategy in the pharmaceutical industry.